Holen Sie sich die Stockscreener-App
186.00
0.49%
-0.91
Handel nachbörslich:
187.50
1.50
+0.81%
Überblick
Nachrichten
Preisverlauf
Optionskette
Financials
Warum fällt BIIB?
Forum
Prognose
Aktiensplit
Schlusskurs vom Vortag:
$186.91
Offen:
$187.02
24-Stunden-Volumen:
1.64M
Relative Volume:
0.86
Marktkapitalisierung:
$27.29B
Einnahmen:
$9.61B
Nettoeinkommen (Verlust:
$1.53B
KGV:
17.79
EPS:
10.453
Netto-Cashflow:
$1.85B
1W Leistung:
+5.69%
1M Leistung:
+3.08%
6M Leistung:
+38.33%
1J Leistung:
+23.38%
1-Tages-Spanne:
$183.50
$187.77
1-Wochen-Bereich:
$171.61
$187.77
52-Wochen-Spanne:
$110.03
$187.77
Biogen Inc Stock (BIIB) Company Profile
Firmenname
Biogen Inc
Sektor
Telefon
(781) 464-2000
Adresse
225 BINNEY STREET, CAMBRIDGE, MA
Vergleichen Sie BIIB mit anderen Aktien
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
BIIB
Biogen Inc
|
186.00 | 27.42B | 9.61B | 1.53B | 1.85B | 10.45 |
|
LLY
Lilly Eli Co
|
1,085.19 | 991.76B | 59.42B | 18.41B | 6.44B | 20.22 |
|
JNJ
Johnson Johnson
|
205.75 | 499.90B | 92.15B | 25.12B | 20.46B | 10.36 |
|
ABBV
Abbvie Inc
|
224.13 | 412.54B | 59.64B | 2.36B | 19.68B | 1.3253 |
|
MRK
Merck Co Inc
|
110.99 | 269.55B | 63.90B | 19.05B | 13.05B | 7.5596 |
|
NVS
Novartis Ag Adr
|
141.46 | 272.43B | 54.45B | 14.42B | 17.15B | 7.333 |
Biogen Inc Stock (BIIB) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2026-01-07 | Fortgesetzt | UBS | Neutral |
| 2025-12-10 | Herabstufung | HSBC Securities | Hold → Reduce |
| 2025-11-06 | Hochstufung | Stifel | Hold → Buy |
| 2025-09-25 | Eingeleitet | Jefferies | Buy |
| 2025-07-21 | Fortgesetzt | Truist | Hold |
| 2025-04-28 | Herabstufung | HSBC Securities | Buy → Hold |
| 2025-04-04 | Herabstufung | Argus | Buy → Hold |
| 2025-02-11 | Eingeleitet | Bernstein | Mkt Perform |
| 2025-01-02 | Herabstufung | Piper Sandler | Overweight → Neutral |
| 2024-12-20 | Herabstufung | BMO Capital Markets | Outperform → Market Perform |
| 2024-12-16 | Herabstufung | Stifel | Buy → Hold |
| 2024-12-10 | Fortgesetzt | BofA Securities | Neutral |
| 2024-12-09 | Herabstufung | Jefferies | Buy → Hold |
| 2024-11-18 | Herabstufung | Needham | Buy → Hold |
| 2024-11-15 | Eingeleitet | Wolfe Research | Peer Perform |
| 2024-11-14 | Eingeleitet | Citigroup | Neutral |
| 2024-10-31 | Herabstufung | Morgan Stanley | Overweight → Equal-Weight |
| 2024-10-10 | Fortgesetzt | Raymond James | Mkt Perform |
| 2024-02-14 | Bestätigt | Needham | Buy |
| 2024-02-14 | Herabstufung | Wells Fargo | Overweight → Equal Weight |
| 2024-01-24 | Herabstufung | UBS | Buy → Neutral |
| 2023-12-20 | Fortgesetzt | Cantor Fitzgerald | Overweight |
| 2023-12-07 | Hochstufung | Raymond James | Mkt Perform → Outperform |
| 2023-09-06 | Eingeleitet | HSBC Securities | Buy |
| 2023-07-27 | Eingeleitet | Scotiabank | Sector Outperform |
| 2023-07-24 | Bestätigt | UBS | Buy |
| 2023-05-01 | Hochstufung | Guggenheim | Neutral → Buy |
| 2023-04-17 | Hochstufung | Piper Sandler | Neutral → Overweight |
| 2022-10-26 | Hochstufung | Goldman | Neutral → Buy |
| 2022-10-13 | Hochstufung | Stifel | Hold → Buy |
| 2022-10-07 | Hochstufung | Argus | Hold → Buy |
| 2022-09-28 | Hochstufung | BMO Capital Markets | Market Perform → Outperform |
| 2022-09-28 | Hochstufung | Mizuho | Neutral → Buy |
| 2022-09-28 | Hochstufung | Robert W. Baird | Neutral → Outperform |
| 2022-04-18 | Hochstufung | Wells Fargo | Equal Weight → Overweight |
| 2022-03-08 | Herabstufung | Stifel | Buy → Hold |
| 2022-03-03 | Hochstufung | RBC Capital Mkts | Sector Perform → Outperform |
| 2022-02-04 | Herabstufung | BMO Capital Markets | Outperform → Market Perform |
| 2022-02-04 | Bestätigt | Barclays | Equal Weight |
| 2022-02-04 | Bestätigt | BofA Securities | Neutral |
| 2022-02-04 | Bestätigt | Cowen | Outperform |
| 2022-02-04 | Bestätigt | Morgan Stanley | Overweight |
| 2022-02-04 | Bestätigt | Needham | Buy |
| 2022-02-04 | Bestätigt | Oppenheimer | Outperform |
| 2022-02-04 | Bestätigt | RBC Capital Mkts | Sector Perform |
| 2022-02-04 | Bestätigt | Robert W. Baird | Neutral |
| 2022-02-04 | Bestätigt | Wedbush | Neutral |
| 2022-02-04 | Bestätigt | Wells Fargo | Equal Weight |
| 2022-02-04 | Bestätigt | Wolfe Research | Peer Perform |
| 2022-01-13 | Herabstufung | Guggenheim | Buy → Neutral |
| 2022-01-12 | Herabstufung | Piper Sandler | Overweight → Neutral |
| 2021-12-10 | Fortgesetzt | Raymond James | Mkt Perform |
| 2021-12-09 | Fortgesetzt | Wells Fargo | Equal Weight |
| 2021-12-06 | Eingeleitet | Goldman | Neutral |
| 2021-11-19 | Eingeleitet | BMO Capital Markets | Outperform |
| 2021-09-23 | Eingeleitet | Needham | Buy |
| 2021-06-18 | Hochstufung | Piper Sandler | Neutral → Overweight |
| 2021-06-14 | Bestätigt | Truist | Buy |
| 2021-06-11 | Hochstufung | Bernstein | Mkt Perform → Outperform |
| 2021-06-10 | Hochstufung | UBS | Neutral → Buy |
| 2021-06-08 | Hochstufung | Atlantic Equities | Underweight → Neutral |
| 2021-06-08 | Bestätigt | Barclays | Equal Weight |
| 2021-06-08 | Hochstufung | Citigroup | Sell → Neutral |
| 2021-06-08 | Bestätigt | H.C. Wainwright | Buy |
| 2021-06-08 | Bestätigt | Jefferies | Buy |
| 2021-06-08 | Bestätigt | Morgan Stanley | Overweight |
| 2021-06-08 | Bestätigt | RBC Capital Mkts | Sector Perform |
| 2021-06-08 | Hochstufung | Robert W. Baird | Underperform → Neutral |
| 2021-06-08 | Bestätigt | Stifel | Buy |
| 2021-06-08 | Hochstufung | William Blair | Mkt Perform → Outperform |
| 2021-06-07 | Hochstufung | BofA Securities | Underperform → Neutral |
| 2021-06-07 | Hochstufung | Cowen | Market Perform → Outperform |
| 2021-06-07 | Hochstufung | Raymond James | Underperform → Mkt Perform |
| 2021-02-05 | Herabstufung | DZ Bank | Buy → Hold |
| 2021-01-29 | Hochstufung | Stifel | Hold → Buy |
| 2020-11-10 | Hochstufung | DZ Bank | Hold → Buy |
| 2020-11-09 | Herabstufung | Atlantic Equities | Neutral → Underweight |
| 2020-11-09 | Herabstufung | BofA Securities | Neutral → Underperform |
| 2020-11-09 | Herabstufung | Cowen | Outperform → Market Perform |
| 2020-11-09 | Bestätigt | H.C. Wainwright | Buy |
| 2020-11-04 | Hochstufung | BofA Securities | Underperform → Neutral |
| 2020-11-04 | Hochstufung | Jefferies | Hold → Buy |
| 2020-11-04 | Hochstufung | Wells Fargo | Equal Weight → Overweight |
| 2020-10-28 | Eingeleitet | UBS | Neutral |
| 2020-07-27 | Hochstufung | Morgan Stanley | Underweight → Overweight |
| 2020-06-22 | Herabstufung | Barclays | Overweight → Equal Weight |
| 2020-06-22 | Bestätigt | RBC Capital Mkts | Sector Perform |
| 2020-06-09 | Herabstufung | Bernstein | Outperform → Mkt Perform |
| 2020-04-23 | Herabstufung | Citigroup | Neutral → Sell |
| 2020-04-23 | Herabstufung | Raymond James | Mkt Perform → Underperform |
| 2020-03-31 | Eingeleitet | Wolfe Research | Peer Perform |
| 2020-02-27 | Eingeleitet | Barclays | Overweight |
| 2020-01-27 | Hochstufung | Canaccord Genuity | Hold → Buy |
| 2019-12-13 | Hochstufung | Credit Suisse | Underperform → Neutral |
| 2019-12-02 | Herabstufung | Robert W. Baird | Neutral → Underperform |
Alle ansehen
Biogen Inc Aktie (BIIB) Neueste Nachrichten
How Biogen Inc. stock performs in high volatility marketsJobs Report & Weekly Watchlist of Top Performers - ulpravda.ru
How Biogen Inc. stock compares to growth peersEarnings Growth Summary & Verified Entry Point Detection - ulpravda.ru
Will Biogen Inc. stock split again soonJuly 2025 EndofMonth & Fast Momentum Stock Entry Tips - ulpravda.ru
What catalysts could drive Biogen Inc. stock higherJuly 2025 Chart Watch & Growth Focused Stock Pick Reports - ulpravda.ru
Truist Securities Raises Price Target for Biogen (BIIB) Amid Hol - GuruFocus
RBC Raises Price Target on Biogen to $220 From $210, Keeps Outperform Rating - MarketScreener
Mizuho raises Biogen stock price target to $207 on improved 2026 catalyst outlook - Investing.com Canada
Biogen : to Report Fourth Quarter and Full Year 2025 Financial Results February 6, 2026 - MarketScreener
Biogen to Report Fourth Quarter and Full Year 2025 Financial Results February 6, 2026 - Biogen
Citigroup Raises Price Target for Biogen (BIIB) to $180, Keeps N - GuruFocus
UBS Adjusts Price Target on Biogen to $185 From $130, Maintains Neutral Rating - MarketScreener
Biogen stock hits 52-week high at 185.59 USD By Investing.com - Investing.com South Africa
Biogen stock hits 52-week high at 185.59 USD - Investing.com
UBS Adjusts Price Target for Biogen (BIIB) with Neutral Rating | - GuruFocus
Analyst Expectations For Biogen's Future - Benzinga
What Biogen (BIIB)'s China Review for At‑Home LEQEMBI Injections Means For Shareholders - Yahoo Finance
Spinal Muscular Atrophy Market Insights 2026-2033: Global - openPR.com
Biogen stock rating maintained at Neutral by UBS, price target raised - Investing.com Canada
Biogen Inc.: Can a Neuroscience Pioneer Still Out-Innovate a Ruthless Market? - AD HOC NEWS
Biogen Inc. stock outperforms competitors on strong trading day - MarketWatch
Biogen to Present at the 44th Annual J.P. Morgan Healthcare Conference - Biogen
Biogen Stock at a Crossroads: Alzheimer Hopes, Biotech Volatility and a Market Running Out of Patien - AD HOC NEWS
Johnson & Johnson Touts Encouraging Results For Experimental Lupus Treatment - Benzinga
Did China’s At‑Home LEQEMBI Review Just Shift Biogen's (BIIB) Alzheimer’s Care Investment Narrative? - simplywall.st
Assessing Biogen (BIIB) Valuation After China Accepts LEQEMBI Subcutaneous License Application - Yahoo Finance
Eisai Announces Biologics License Application for the Subcutaneous Formulation of Leqembi for Treatment of Early Alzheimer's Disease - MarketScreener
Biogen (BIIB) Receives a Hold from Bank of America Securities - The Globe and Mail
Will Biogen Inc. stock benefit from sector rotationSwing Trading Ideas & Small Investment Trading Plans - bollywoodhelpline.com
Biogen’s Stock Awaits Key Regulatory Catalyst in China - AD HOC NEWS
BIIB: Biogen's LEQEMBI Application Accepted in China - GuruFocus
Eisai and Biogen Announce Acceptance of Biologics License Application for Subcutaneous LEQEMBI® in China - Quiver Quantitative
Biogen : Biologics License Application for Subcutaneous Formulation of “LEQEMBI®” (lecanemab) for the Treatment of Early Alzheimer’s Disease Accepted in China - marketscreener.com
Biologics License Application for Subcutaneous Formulation of “LEQEMBI®” (lecanemab) for the Treatment of Early Alzheimer’s Disease Accepted in China - Biogen
Biologics License Application for Subcutaneous Formulation - GlobeNewswire
Biogen Inc. stock underperforms Monday when compared to competitors - MarketWatch
Samsung Bioepis Begins Commercialization of BYOOVIZ®, Biosimilar to Lucentis (Ranibizumab), in Europe - BioSpace
Inside Biotech: A potential paradigm shift in Alzheimer’s therapy — reversal, not just slowing - Proactive financial news
Biogen Inc. (BIIB) Stock Price | Live Quotes & Charts | NASDAQ - StocksToTrade
Biosimilars Market is expected to reach US$ 171.79 billion - openPR.com
Biogen Inc. $BIIB Stock Position Increased by Cwm LLC - MarketBeat
Biotech pioneer who helped launch Biogen dies at 94 - The Business Journals
Biogen: Competing With Eli Lilly's Kisunla, Safety Gives Market Edge (NASDAQ:BIIB) - Seeking Alpha
Dementia Drugs Market 2025 Outlook: In-Depth Insights, - openPR.com
Ethic Inc. Boosts Stake in Biogen Inc. $BIIB - MarketBeat
Spinal Muscular Atrophy Market is expected to reach US$ 20.06 - openPR.com
Recombinant Therapeutic Antibodies And Proteins Market - openPR.com
J. L. Bainbridge & Co. Inc. Cuts Holdings in Biogen Inc. $BIIB - MarketBeat
Vontobel Holding Ltd. Sells 18,760 Shares of Biogen Inc. $BIIB - MarketBeat
Pacer Advisors Inc. Acquires 131,258 Shares of Biogen Inc. $BIIB - MarketBeat
Cns Specific Antisense Oligonucleotide MarketForecast - openPR.com
Swedbank AB Grows Stake in Biogen Inc. $BIIB - MarketBeat
Finanzdaten der Biogen Inc-Aktie (BIIB)
Umsatz
Nettogewinn
Free Cashflow
ENV
0.50%
0.04%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):